Capricor Therapeutics Investors Face September Deadline in Fraud Suit

The lawsuit centers on claims that Capricor executives issued misleading statements regarding the development of Deramiocel, a treatment for Duchenne muscular dystrophy. According to the complaint, the company modified its statistical analysis plan for clinical trial data without securing prior FDA approval. This omission allegedly obscured significant regulatory risks, leaving investors unaware that the clinical results might fail to meet federal standards for effectiveness.

By failing to disclose these internal adjustments before resubmitting their Biologics License Application, defendants reportedly created a false impression of the drug's path to market. Shareholders interested in participating in the action or seeking legal clarification are encouraged to contact the firm by the late-September deadline. Participation does not require immediate action, as potential class members retain the right to select their own counsel or remain absent from the proceedings.